Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer

J Natl Cancer Inst. 1995 Aug 16;87(16):1254-6. doi: 10.1093/jnci/87.16.1254.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Methotrexate / administration & dosage
  • Neoplasm Proteins / analysis*
  • Predictive Value of Tests
  • Prednisone / administration & dosage
  • Proportional Hazards Models
  • Risk
  • Survival Analysis
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / analysis*

Substances

  • Neoplasm Proteins
  • Tumor Suppressor Protein p53
  • Cyclophosphamide
  • Fluorouracil
  • Prednisone
  • Methotrexate